Clinical trials: Empagliflozin
Hyponatremia, SIADH
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Hyponatremia is the most common electrolyte derangement occurring in hospitalized patients. It is usually classified as hypovolemic, euvolemic or hypervolemic.
- Conditions
- Hyponatremia, SIADH, Liver Failure, Kidney Failure
- Trial name
- EMPOWER (NCT04447911)
- Testing
- Empagliflozin 25 MG
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 113 people
- Sponsor
- University Hospital, Basel, Switzerland
Diabetes
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04215536
- Testing
- Empagliflozin, DPP-4 inhibitor
- Where
- United States
- Volunteers
- 103,752 people
- Sponsor
- Brigham and Women's Hospital
Diabetes Mellitus, Type 2
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
The objectives of this study are to assess the risk of ketoacidosis, severe urinary tract infections, volume depletion, and dehydration associated in patients with T2DM initiating Empagliflozin compared to patient initiating a…
- Trial name
- NCT03764631
- Testing
- Empagliflozin, Dipeptidyl-peptidase 4 (DPP-4) inhibitors
- Where
- 21 sites in Saudi Arabia
- Volunteers
- 1,502 people
- Sponsor
- Boehringer Ingelheim
Healthy
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Bioequivalence of two 12.5 mg empagliflozin/500 mg metformin fixed dose combination tablets compared to the free combination of empagliflozin 25 mg and metformin 1000 mg in healthy male and female volunteers under fed conditions
- Trial name
- NCT02577315
- Testing
- Empagliflozin, Metformin
- Where
- Russia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Acute Kidney Injury
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
SGLT2i have been shown to reduce risk for mortality, progression of chronic kidney disease, and cardiovascular outcomes in these populations.
- Trial name
- NCT06124924
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Minnesota
Congenital Heart Disease, Heart Failure
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population.
- Conditions
- Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- NCT05580510
- Testing
- Sacubitril 49 MG / Valsartan 51 MG [Entresto] BID, Empagliflozin 10 MG OD
- Where
- Mexico
- Volunteers
- 160 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Diabetes Mellitus Type 2
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Empagliflozin and metformin hydrochloride are two separate drugs. The combination of these two drugs in one tablet are used for the treatment of type 2 diabetes, along with diet and exercise, and can be used with other drugs, if…
- Trial name
- NCT06792968
- Testing
- Empagliflozin + Metformin hydrochloride 5 mg/1000 mg combination film-coated tablets, Synjardy 5 mg/1000 mg film-coated tablets
- Where
- Russia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Gedeon Richter Plc.
Heart Failure With Reduced Ejection Fraction
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
The study is a short to mid-term randomized single-blind placebo controlled study that aimed to detect the effects of empagliflozin (a sodium-glucose cotransporter-2 inhibitor) compared to placebo on LV end-diastolic and…
- Trial name
- HFrEF (NCT06632561)
- Testing
- Empagliflozin 10 mg
- Where
- Egypt
- Volunteers
- 74 people
- Sponsor
- Ashraf Wasfy Beshay Aziz
Blood Pressure, Endothelial Dysfunction
Neurovascular Effects of Empagliflozin
The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension.
- Trial name
- NEURO-EMPA (NCT07799441)
- Testing
- Empagliflozin (EMPA)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kanokwan Bunsawat
Pre-Diabetes, Weight, Body
Prevention of Progression of Prediabetes, Obesity and CV Risk
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.
- Conditions
- Pre-Diabetes, Weight, Body, Cardiovascular Diseases
- Trial name
- Pre-DM (NCT06446531)
- Testing
- Rybelsus Tablet, Jardiance 25Mg Tablet, Metformin
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Partial Islet Function, TPIAT
SGLT2i Therapy in Islet Transplantation (SIT)
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who…
- Conditions
- Partial Islet Function, TPIAT, Diabetes
- Trial name
- NCT07228195
- Testing
- Empagliflozin 25 MG Oral Tablet, Empagliflozin 10 MG Oral Tablet [Jardiance]
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes
This study evaluates the efficacy and safety of the empagliflozin as add-on thearpy compared to insulin glargine-based antidiabetic agents (OADs) combination thearpy in patients with type 2 diabetes inadequately controlled on…
- Trial name
- NCT03473262
- Volunteers
- 200 people
- Sponsor
- Chungbuk National University Hospital
DW6014
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fed condition.
- Trial name
- NCT05823883
- Testing
- DW6014
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Alzheimer Disease
Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease
The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an…
- Trial name
- REVITAA-ALZ (NCT07756294)
- Testing
- Empagliflozin, Insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Heart Failure With Preserved Ejection Fraction
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Heart Failure (HF) in Australia affects 1-2% of the population. Heart failure with preserved ejection fraction (HFpEF) refers to a syndrome of clinical heart failure without impairment of systolic cardiac function.
- Trial name
- NCT05129722
- Testing
- Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin
- Where
- 2 sites in Australia
- Volunteers
- 3 people
- Sponsor
- The George Institute
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic…
- Trial name
- NCT01167881
- Testing
- BI 10773, Glimepiride
- Where
- 182 sites in United States, Argentina and 21 more
- Volunteers
- 1,549 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
The objective of this study is to assess the effect of the different degrees of renal impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral administration of high dose BI10773 as a single dose…
- Trial name
- NCT01581658
- Testing
- BI10773
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Cardiogenic Shock
Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial
Despite advancements in treatment, the mortality rate for cardiogenic shock (CS) remains high at around 50%. The EMPULSE-HF trial showed that early introduction of empagliflozin in stabilized patients with acute heart failure led…
- Trial name
- EMPAmicroSHOCK (NCT07141355)
- Testing
- microcirculation using the video microscopy tool.
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Strasbourg, France
Type 2 Diabetes
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
Patients with type 2 diabetes (T2D) suffer from an excess risk of adverse cardiovascular events. Recently, two classes of glucose lowering agents, namely SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA), have…
- Trial name
- NCT04184947
- Testing
- SGLT2 inhibitor, GLP-1 receptor agonist
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- University of Padova
Heart Failure
Effects of Acute and Chronic Empagliflozin Heart Failure
This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes.
- Trial name
- EMPA HF (NCT05553938)
- Testing
- Empagliflozin 10 mg
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Yale University